Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 188.02M
June 30, 2026 211.67M
March 31, 2026 220.36M
December 31, 2025 222.70M
September 30, 2025 218.21M
June 30, 2025 204.42M
March 31, 2025 190.17M
December 31, 2024 178.89M
September 30, 2024 173.78M
June 30, 2024 179.46M
March 31, 2024 176.88M
December 31, 2023 172.47M
September 30, 2023 159.47M
June 30, 2023 138.73M
March 31, 2023 127.71M
December 31, 2022 111.02M
September 30, 2022 100.32M
June 30, 2022 91.63M
Date Value
March 31, 2022 80.64M
December 31, 2021 75.03M
September 30, 2021 69.81M
June 30, 2021 63.99M
March 31, 2021 57.49M
December 31, 2020 54.72M
September 30, 2020 51.80M
June 30, 2020 45.68M
March 31, 2020 40.81M
December 31, 2019 32.47M
September 30, 2019 28.90M
June 30, 2019 25.69M
March 31, 2019 22.17M
December 31, 2018 21.26M
September 30, 2018 16.97M
June 30, 2018 15.16M
March 31, 2018 13.52M
December 31, 2017 11.50M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
PepGen Inc. 52.70M
Oncolytics Biotech, Inc. 13.18M
Sangamo Therapeutics, Inc. 113.79M
Sarepta Therapeutics, Inc. 647.26M
Anixa Biosciences, Inc. 4.828M